troglitazone has been researched along with Metabolic Diseases in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Metabolic Diseases: Generic term for diseases caused by an abnormal metabolic process. It can be congenital due to inherited enzyme abnormality (METABOLISM, INBORN ERRORS) or acquired due to disease of an endocrine organ or failure of a metabolically important organ such as the liver. (Stedman, 26th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| " In the present study, we used Otsuka Long-Evans Tokushima Fatty (OLETF) rats, which exhibit hypertension, obesity, severe hyperglycemia and hypertriglyceridemia, and are thus considered an animal model of atherogenic disease, to test the effects of oral administration of troglitazone (200 mg/kg) on renal klotho mRNA expression and endothelial function." | 3.71 | Troglitazone improves endothelial function and augments renal klotho mRNA expression in Otsuka Long-Evans Tokushima Fatty (OLETF) rats with multiple atherogenic risk factors. ( Kanai, H; Kurabayashi, M; Kuro-o, M; Nabeshima, Y; Nagai, R; Nakamura, T; Saito, Y; Sumino, H; Takeda, S; Yamagishi, T, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yamagishi, T | 1 |
| Saito, Y | 1 |
| Nakamura, T | 1 |
| Takeda, S | 1 |
| Kanai, H | 1 |
| Sumino, H | 1 |
| Kuro-o, M | 1 |
| Nabeshima, Y | 1 |
| Kurabayashi, M | 1 |
| Nagai, R | 1 |
1 other study available for troglitazone and Metabolic Diseases
| Article | Year |
|---|---|
Troglitazone improves endothelial function and augments renal klotho mRNA expression in Otsuka Long-Evans Tokushima Fatty (OLETF) rats with multiple atherogenic risk factors.
Topics: Animals; Arteriosclerosis; Chromans; Endothelium, Vascular; Glucuronidase; Hypertension; Kidney; Klo | 2001 |